UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Medtronic

M

Medtronic

Visit Website

About Medtronic

Medtronic is the world's largest dedicated medical device company, with a history stretching back to 1949 when Earl Bakken and Palmer Hermundslie founded it in a Minneapolis garage. Today headquartered in Dublin, Ireland, with operational headquarters in Fridley, Minnesota, the company employs over 90,000 people across more than 150 countries, making it a defining force in the global medical technology industry.

Therapy Areas and Product Portfolio

Medtronic operates across four principal business segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its cardiovascular portfolio includes pacemakers, defibrillators, heart valves, and structural heart therapies. The neuroscience segment covers deep brain stimulation systems, spinal cord stimulators, neurovascular devices, and surgical navigation platforms. The medical surgical division encompasses advanced energy tools, gastrointestinal diagnostics, and respiratory interventions. The diabetes segment produces insulin pumps and continuous glucose monitoring technology, including the widely adopted MiniMed systems.

Innovation and Global Reach

Listed on the New York Stock Exchange under the ticker MDT, Medtronic is a component of the S&P 500 and consistently ranks among the largest healthcare companies by market capitalisation. The company invests heavily in research and development, maintaining a substantial pipeline of next-generation devices and minimally invasive therapies. Its robotic-assisted surgical platform, the Hugo system, reflects broader ambitions in digital health and surgical robotics. Medtronic also operates one of the largest physician training and education networks in the medical device sector, supporting clinicians across specialties worldwide.

The company's reach extends into emerging markets through dedicated access programmes, and it has made numerous strategic acquisitions over decades to strengthen capabilities across its core segments. Medtronic's scale, diversification across device categories, and long-standing relationships with hospital systems globally position it as an essential reference for procurement, partnership, and industry intelligence within the medical technology sector.

Further information is available at medtronic.com.

Similar Companies

More in Cardiovascular & Metabolic

N

Novartis

Novartis ranks among the world's largest pharmaceutical companies, built on the 1996 merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical giants with roots stretching back to the nineteenth century. Headquartered in Basel, Switzerland, the company operates across more than 100 countries and employs hundreds of thousands of people globally, making it one of the defining organisations in modern medicine. Innovative Medicines The core innovative medicines division focuses on developing and commercialising patented treatments across a concentrated set of therapeutic areas. Oncology is a particular strength, with the company having established early leadership in targeted cancer therapies, including kinase inhibitors that reshaped haematology. Cardiovascular, immunology, neuroscience, and ophthalmology round out the primary focus areas. The company's cell and gene therapy ambitions are embodied in platforms that have drawn significant industry attention, positioning Novartis at the frontier of advanced therapeutic modalities. Sandoz & the Generics Legacy For much of its post-merger history, Novartis operated a substantial generics and biosimilars business under the Sandoz brand. In 2023, Sandoz was spun off as an independent publicly traded company, sharpening Novartis's focus entirely on patented innovative medicines. The separation reflected a broader strategic decision to concentrate resources where the company sees its strongest long-term competitive position. Novartis is listed on the SIX Swiss Exchange under the ticker NOVN and on the New York Stock Exchange as NVS, giving it access to deep capital markets to fund its substantial research and development programme. The company consistently ranks among the top spenders on pharmaceutical R&D globally, operating research facilities across Europe, North America, and Asia. Radioligand therapy represents one of the newer strategic bets, combining targeted delivery mechanisms with therapeutic isotopes, an area Novartis has pursued through acquisitions and internal development. The company's commercial pipeline and approved portfolio span small molecules, biologics, and cell-based therapies, reflecting the breadth of its scientific capabilities. Further information is available at novartis.com.

View profile
C

Covis Pharma

Covis Pharma built its model around acquiring and commercialising established, off-patent branded medicines that larger pharmaceutical companies no longer prioritise, giving those products renewed focus and commercial investment. Founded in 2011 and headquartered in Zug, Switzerland, the company operates internationally with a significant commercial presence across Europe and North America. The portfolio centres on specialty and hospital medicines, with particular depth in cardiovascular, respiratory, and women's health therapy areas. Key marketed products include treatments for heart failure, hypertension, and related cardiovascular conditions, alongside respiratory medicines and products addressing acute obstetric and gynaecological needs. Rather than pursuing early-stage drug discovery, Covis focuses on lifecycle management and ensuring continued patient access to medicines that retain clinical relevance. Covis operates through direct commercial infrastructure in multiple European markets and partners with distributors and co-promotion arrangements where its own footprint does not reach. The company has grown substantially through a series of portfolio acquisitions from major pharmaceutical groups, adding assets that benefit from dedicated commercial attention rather than competing for resources within large multinational pipelines. The business is privately held and backed by Apollo Global Management, which has supported its acquisition-led growth strategy. This structure allows Covis to move with relative speed on asset deals and to take a long-term view on branded generics and mature specialty products that still address unmet patient needs in their therapeutic categories. Further information is available at covispharma.com.

View profile
V

Viatris

Born from the 2020 combination of Mylan and Pfizer's Upjohn division, Viatris operates as one of the world's largest generic and established medicines companies, serving patients across more than 165 countries with a portfolio spanning both off-patent generics and branded products. The company's founding premise was to bridge the gap between innovation and access, ensuring that essential medicines reach patients regardless of geography or economic circumstance. Portfolio Breadth and Therapeutic Reach Viatris maintains a catalogue of approximately 1,400 molecules covering a wide range of therapeutic areas, including cardiovascular disease, infectious disease, central nervous system conditions, oncology, immunology, and respiratory health. The company is recognised as a leading global supplier of antiretrovirals for HIV treatment, a position inherited in part from Mylan's longstanding role in global health programmes. Its branded medicines include well-known products such as Lipitor (atorvastatin) and EpiPen, alongside an extensive generics and complex generics pipeline. Global Manufacturing and Access Mission Headquartered in Canonsburg, Pennsylvania, USA, and incorporated in 2020, Viatris operates a substantial global manufacturing network with facilities across North America, Europe, and Asia. The company is publicly listed on the Nasdaq exchange under the ticker symbol VTRS. Its scale enables a dual mandate: competing commercially in mature markets while actively supplying low- and middle-income countries through tiered pricing and partnership agreements with international health bodies. Viatris has also pursued a strategic refocusing in recent years, divesting certain assets to concentrate resources on higher-value complex generics, biosimilars, and brand-name medicines. The biosimilars segment represents a growing area of investment, with the company working to commercialise alternatives to complex biologics across key markets. This evolution reflects a broader industry shift as the patent cliff for major biologics opens new competition opportunities for experienced generics manufacturers. Further information is available at viatris.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy